Study to evaluate immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals’ Inactivated Polio Vaccine (Poliorix) in healthy Chinese toddlers

Update Il y a 4 ans
Reference: EUCTR2012-004513-14

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To assess the immunological response to a booster dose of GSK Biologicals’ IPV in terms of poliovirus type 1, 2 and 3 antibodies, one month after the booster dose in subjects primed with three doses of the same IPV vaccine in study IPV-018. To assess the persistence of antibodies to poliovirus types 1, 2 and 3 antigens at 18 months of age in subjects primed with three doses of GSK Biologicals’ IPV or three doses of OPV in study IPV-018.


Inclusion criteria

  • Booster immunisation of healthy children in the second year of life against poliomyelitis

Links